Cargando…
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
Anagliptin is a novel dipeptidyl peptidase-4 inhibitor that has been available in Japan since 2012. Because anagliptin is not generally used in countries other than Japan, there are only a small number of reports investigating the effects of anagliptin. In the present article, we review the safety a...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370682/ https://www.ncbi.nlm.nih.gov/pubmed/25834461 http://dx.doi.org/10.2147/DMSO.S54679 |